A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma.

Trial Profile

A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Cetuximab; Cyclophosphamide; Tumour cell vaccine-GVAX
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 14 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 13 Oct 2009 Planned end date added to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClincalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top